Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2012

Open Access 01-12-2012 | Original investigation

Predictive value of advanced glycation end products for the development of post-infarction heart failure: a preliminary report

Authors: Sergio Raposeiras-Roubín, Bruno K Rodiño-Janeiro, Beatriz Paradela-Dobarro, Lilian Grigorian-Shamagian, José M García-Acuña, Pablo Aguiar-Souto, Michel Jacquet-Hervet, María V Reino-Maceiras, Ezequiel Álvarez, José R González-Juanatey

Published in: Cardiovascular Diabetology | Issue 1/2012

Login to get access

Abstract

Background

Since post-infarction heart failure (HF) determines a great morbidity and mortality, and given the physiopathology implications of advanced glycation end products (AGE) in the genesis of myocardial dysfunction, it was intended to analyze the prognostic value of these molecules in order to predict post-infarction HF development.

Methods

A prospective clinical study in patients after first acute coronary syndrome was conducted. The follow-up period was consisted in 1 year. In 194 patients consecutively admitted in the coronary unit for myocardial infarct fluorescent AGE levels were measured. The association between glycaemic parameters and the development of post-infarction HF were analyzed in those patients. Finally, we identified the variables with independent predictor value by performing a multivariate analysis of Hazard ratio for Cox regression.

Results

Eleven out of 194 patients (5.6%) developed HF during follow-up (median: 1.0 years [0.8 - 1.5 years]). Even though basal glucose, fructosamine and glycated haemoglobin were significant predictive factors in the univariate analysis, after being adjusted by confounding variables and AGE they lost their statistical signification. Only AGE (Hazard Ratio 1.016, IC 95%: 1.006-1.026; p<0,001), together with NT-proBNP and the infarct extension were predictors for post-infarction HF development, where AGE levels over the median value 5-fold increased the risk of HF development during follow-up.

Conclusions

AGE are an independent marker of post-infarction HF development risk.
Appendix
Available only for authorised users
Literature
1.
go back to reference Macchia A, Levantesi G, Marfisi RM, Franzosi MG, Maggioni AP, Nicolosi GL, Schweiger C, Tavazzi L, Tognoni G, Valagussa F, et al: Determinants of late-onset heart failure in myocardial infarction survivors: GISSI Prevenzione trial results. Rev Esp Cardiol. 2005, 58 (11): 1266-1272. 10.1157/13080953.CrossRefPubMed Macchia A, Levantesi G, Marfisi RM, Franzosi MG, Maggioni AP, Nicolosi GL, Schweiger C, Tavazzi L, Tognoni G, Valagussa F, et al: Determinants of late-onset heart failure in myocardial infarction survivors: GISSI Prevenzione trial results. Rev Esp Cardiol. 2005, 58 (11): 1266-1272. 10.1157/13080953.CrossRefPubMed
2.
go back to reference Gajarsa JJ, Kloner RA: Left ventricular remodeling in the post-infarction heart: a review of cellular, molecular mechanisms, and therapeutic modalities. Heart Fail Rev. 2011, 16 (1): 13-21. 10.1007/s10741-010-9181-7.CrossRefPubMed Gajarsa JJ, Kloner RA: Left ventricular remodeling in the post-infarction heart: a review of cellular, molecular mechanisms, and therapeutic modalities. Heart Fail Rev. 2011, 16 (1): 13-21. 10.1007/s10741-010-9181-7.CrossRefPubMed
3.
go back to reference Cohn JN, Ferrari R, Sharpe N: Cardiac remodeling–concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol. 2000, 35 (3): 569-582. 10.1016/S0735-1097(99)00630-0.CrossRefPubMed Cohn JN, Ferrari R, Sharpe N: Cardiac remodeling–concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol. 2000, 35 (3): 569-582. 10.1016/S0735-1097(99)00630-0.CrossRefPubMed
4.
go back to reference Roig Minguell E: Clinical use of markers of neurohormonal activation in heart failure. Rev Esp Cardiol. 2004, 57 (4): 347-356. 10.1157/13059727.CrossRefPubMed Roig Minguell E: Clinical use of markers of neurohormonal activation in heart failure. Rev Esp Cardiol. 2004, 57 (4): 347-356. 10.1157/13059727.CrossRefPubMed
5.
go back to reference Dominguez Rodriguez A, Abreu Gonzalez P, Garcia Gonzalez MJ, Ferrer Hita J: Association between serum interleukin 10 level and development of heart failure in acute myocardial infarction patients treated by primary angioplasty. Rev Esp Cardiol. 2005, 58 (6): 626-630. 10.1157/13076414.CrossRefPubMed Dominguez Rodriguez A, Abreu Gonzalez P, Garcia Gonzalez MJ, Ferrer Hita J: Association between serum interleukin 10 level and development of heart failure in acute myocardial infarction patients treated by primary angioplasty. Rev Esp Cardiol. 2005, 58 (6): 626-630. 10.1157/13076414.CrossRefPubMed
6.
go back to reference Held C, Gerstein HC, Yusuf S, Zhao F, Hilbrich L, Anderson C, Sleight P, Teo K: Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk. Circulation. 2007, 115 (11): 1371-1375. 10.1161/CIRCULATIONAHA.106.661405.CrossRefPubMed Held C, Gerstein HC, Yusuf S, Zhao F, Hilbrich L, Anderson C, Sleight P, Teo K: Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk. Circulation. 2007, 115 (11): 1371-1375. 10.1161/CIRCULATIONAHA.106.661405.CrossRefPubMed
7.
go back to reference Pazin-Filho A, Kottgen A, Bertoni AG, Russell SD, Selvin E, Rosamond WD, Coresh J: HbA 1c as a risk factor for heart failure in persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) study. Diabetologia. 2008, 51 (12): 2197-2204. 10.1007/s00125-008-1164-z.CrossRefPubMed Pazin-Filho A, Kottgen A, Bertoni AG, Russell SD, Selvin E, Rosamond WD, Coresh J: HbA 1c as a risk factor for heart failure in persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) study. Diabetologia. 2008, 51 (12): 2197-2204. 10.1007/s00125-008-1164-z.CrossRefPubMed
8.
go back to reference Matsushita K, Blecker S, Pazin-Filho A, Bertoni A, Chang PP, Coresh J, Selvin E: The association of hemoglobin a1c with incident heart failure among people without diabetes: the atherosclerosis risk in communities study. Diabetes. 2010, 59 (8): 2020-2026. 10.2337/db10-0165.PubMedCentralCrossRefPubMed Matsushita K, Blecker S, Pazin-Filho A, Bertoni A, Chang PP, Coresh J, Selvin E: The association of hemoglobin a1c with incident heart failure among people without diabetes: the atherosclerosis risk in communities study. Diabetes. 2010, 59 (8): 2020-2026. 10.2337/db10-0165.PubMedCentralCrossRefPubMed
9.
go back to reference Wolffenbuttel BH, Giordano D, Founds HW, Bucala R: Long-term assessment of glucose control by haemoglobin-AGE measurement. Lancet. 1996, 347 (9000): 513-515. 10.1016/S0140-6736(96)91141-1.CrossRefPubMed Wolffenbuttel BH, Giordano D, Founds HW, Bucala R: Long-term assessment of glucose control by haemoglobin-AGE measurement. Lancet. 1996, 347 (9000): 513-515. 10.1016/S0140-6736(96)91141-1.CrossRefPubMed
10.
go back to reference Basta G, Lazzerini G, Massaro M, Simoncini T, Tanganelli P, Fu C, Kislinger T, Stern DM, Schmidt AM, De Caterina R: Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation. 2002, 105 (7): 816-822. 10.1161/hc0702.104183.CrossRefPubMed Basta G, Lazzerini G, Massaro M, Simoncini T, Tanganelli P, Fu C, Kislinger T, Stern DM, Schmidt AM, De Caterina R: Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation. 2002, 105 (7): 816-822. 10.1161/hc0702.104183.CrossRefPubMed
12.
go back to reference Hartog JW, Voors AA, Bakker SJ, Smit AJ, van Veldhuisen DJ: Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications. Eur J Heart Fail. 2007, 9 (12): 1146-1155. 10.1016/j.ejheart.2007.09.009.CrossRefPubMed Hartog JW, Voors AA, Bakker SJ, Smit AJ, van Veldhuisen DJ: Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications. Eur J Heart Fail. 2007, 9 (12): 1146-1155. 10.1016/j.ejheart.2007.09.009.CrossRefPubMed
13.
go back to reference Thygesen K, Alpert JS, White HD, Jaffe AS, Apple FS, Galvani M, Katus HA, Newby LK, Ravkilde J, Chaitman B, et al: Universal definition of myocardial infarction. Circulation. 2007, 116 (22): 2634-2653. 10.1161/CIRCULATIONAHA.107.187397.CrossRefPubMed Thygesen K, Alpert JS, White HD, Jaffe AS, Apple FS, Galvani M, Katus HA, Newby LK, Ravkilde J, Chaitman B, et al: Universal definition of myocardial infarction. Circulation. 2007, 116 (22): 2634-2653. 10.1161/CIRCULATIONAHA.107.187397.CrossRefPubMed
14.
go back to reference American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010, 34 (Suppl 1): S62-S69.CrossRef American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010, 34 (Suppl 1): S62-S69.CrossRef
15.
go back to reference Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernandez-Aviles F, Fox KA, Hasdai D, Ohman EM, Wallentin L, et al: Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007, 28 (13): 1598-1660.CrossRefPubMed Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernandez-Aviles F, Fox KA, Hasdai D, Ohman EM, Wallentin L, et al: Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007, 28 (13): 1598-1660.CrossRefPubMed
16.
go back to reference Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, Filippatos G, Fox K, Huber K, Kastrati A, et al: Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the task force on the management of ST-segment elevation acute myocardial infarction of the European society of cardiology. Eur Heart J. 2008, 29 (23): 2909-2945.CrossRefPubMed Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, Filippatos G, Fox K, Huber K, Kastrati A, et al: Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the task force on the management of ST-segment elevation acute myocardial infarction of the European society of cardiology. Eur Heart J. 2008, 29 (23): 2909-2945.CrossRefPubMed
17.
go back to reference Munch G, Keis R, Wessels A, Riederer P, Bahner U, Heidland A, Niwa T, Lemke HD, Schinzel R: Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA. Eur J Clin Chem Clin Biochem. 1997, 35 (9): 669-677.PubMed Munch G, Keis R, Wessels A, Riederer P, Bahner U, Heidland A, Niwa T, Lemke HD, Schinzel R: Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA. Eur J Clin Chem Clin Biochem. 1997, 35 (9): 669-677.PubMed
18.
go back to reference Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, et al: ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail. 2008, 10 (10): 933-989. 10.1016/j.ejheart.2008.08.005.CrossRefPubMed Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, et al: ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail. 2008, 10 (10): 933-989. 10.1016/j.ejheart.2008.08.005.CrossRefPubMed
19.
go back to reference Lewis EF, Solomon SD, Jablonski KA, Rice MM, Clemenza F, Hsia J, Maggioni AP, Zabalgoitia M, Huynh T, Cuddy TE, et al: Predictors of heart failure in patients with stable coronary artery disease: a PEACE study. Circ Heart Fail. 2009, 2 (3): 209-216. 10.1161/CIRCHEARTFAILURE.108.820696.PubMedCentralCrossRefPubMed Lewis EF, Solomon SD, Jablonski KA, Rice MM, Clemenza F, Hsia J, Maggioni AP, Zabalgoitia M, Huynh T, Cuddy TE, et al: Predictors of heart failure in patients with stable coronary artery disease: a PEACE study. Circ Heart Fail. 2009, 2 (3): 209-216. 10.1161/CIRCHEARTFAILURE.108.820696.PubMedCentralCrossRefPubMed
20.
go back to reference Koyama Y, Takeishi Y, Arimoto T, Niizeki T, Shishido T, Takahashi H, Nozaki N, Hirono O, Tsunoda Y, Nitobe J, et al: High serum level of pentosidine, an advanced glycation end product (AGE), is a risk factor of patients with heart failure. J Card Fail. 2007, 13 (3): 199-206. 10.1016/j.cardfail.2006.11.009.CrossRefPubMed Koyama Y, Takeishi Y, Arimoto T, Niizeki T, Shishido T, Takahashi H, Nozaki N, Hirono O, Tsunoda Y, Nitobe J, et al: High serum level of pentosidine, an advanced glycation end product (AGE), is a risk factor of patients with heart failure. J Card Fail. 2007, 13 (3): 199-206. 10.1016/j.cardfail.2006.11.009.CrossRefPubMed
21.
go back to reference Hartog JW, Voors AA, Schalkwijk CG, Scheijen J, Smilde TD, Damman K, Bakker SJ, Smit AJ, van Veldhuisen DJ: Clinical and prognostic value of advanced glycation end-products in chronic heart failure. Eur Heart J. 2007, 28 (23): 2879-2885. 10.1093/eurheartj/ehm486.CrossRefPubMed Hartog JW, Voors AA, Schalkwijk CG, Scheijen J, Smilde TD, Damman K, Bakker SJ, Smit AJ, van Veldhuisen DJ: Clinical and prognostic value of advanced glycation end-products in chronic heart failure. Eur Heart J. 2007, 28 (23): 2879-2885. 10.1093/eurheartj/ehm486.CrossRefPubMed
22.
go back to reference Aronson D: Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J Hypertens. 2003, 21 (1): 3-12. 10.1097/00004872-200301000-00002.CrossRefPubMed Aronson D: Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J Hypertens. 2003, 21 (1): 3-12. 10.1097/00004872-200301000-00002.CrossRefPubMed
23.
go back to reference Cipollone F, Iezzi A, Fazia M, Zucchelli M, Pini B, Cuccurullo C, De Cesare D, De Blasis G, Muraro R, Bei R, et al: The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation. 2003, 108 (9): 1070-1077. 10.1161/01.CIR.0000086014.80477.0D.CrossRefPubMed Cipollone F, Iezzi A, Fazia M, Zucchelli M, Pini B, Cuccurullo C, De Cesare D, De Blasis G, Muraro R, Bei R, et al: The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation. 2003, 108 (9): 1070-1077. 10.1161/01.CIR.0000086014.80477.0D.CrossRefPubMed
24.
go back to reference Petrova R, Yamamoto Y, Muraki K, Yonekura H, Sakurai S, Watanabe T, Li H, Takeuchi M, Makita Z, Kato I, et al: Advanced glycation endproduct-induced calcium handling impairment in mouse cardiac myocytes. J Mol Cell Cardiol. 2002, 34 (10): 1425-1431. 10.1006/jmcc.2002.2084.CrossRefPubMed Petrova R, Yamamoto Y, Muraki K, Yonekura H, Sakurai S, Watanabe T, Li H, Takeuchi M, Makita Z, Kato I, et al: Advanced glycation endproduct-induced calcium handling impairment in mouse cardiac myocytes. J Mol Cell Cardiol. 2002, 34 (10): 1425-1431. 10.1006/jmcc.2002.2084.CrossRefPubMed
25.
go back to reference Soro-Paavonen A, Zhang WZ, Venardos K, Coughlan MT, Harris E, Tong DC, Brasacchio D, Paavonen K, Chin-Dusting J, Cooper ME, et al: Advanced glycation end-products induce vascular dysfunction via resistance to nitric oxide and suppression of endothelial nitric oxide synthase. J Hypertens. 2010, 28 (4): 780-788. 10.1097/HJH.0b013e328335043e.CrossRefPubMed Soro-Paavonen A, Zhang WZ, Venardos K, Coughlan MT, Harris E, Tong DC, Brasacchio D, Paavonen K, Chin-Dusting J, Cooper ME, et al: Advanced glycation end-products induce vascular dysfunction via resistance to nitric oxide and suppression of endothelial nitric oxide synthase. J Hypertens. 2010, 28 (4): 780-788. 10.1097/HJH.0b013e328335043e.CrossRefPubMed
26.
go back to reference Wang J, Liu H, Chen B, Li Q, Huang X, Wang L, Guo X, Huang Q: RhoA/ROCK-dependent moesin phosphorylation regulates AGE-induced endothelial cellular response. Cardiovasc Diabetol. 2012, 11: 7-10.1186/1475-2840-11-7.PubMedCentralCrossRefPubMed Wang J, Liu H, Chen B, Li Q, Huang X, Wang L, Guo X, Huang Q: RhoA/ROCK-dependent moesin phosphorylation regulates AGE-induced endothelial cellular response. Cardiovasc Diabetol. 2012, 11: 7-10.1186/1475-2840-11-7.PubMedCentralCrossRefPubMed
27.
go back to reference Li H, Zhang X, Guan X, Cui X, Wang Y, Chu H, Cheng M: Advanced glycation end products impair the migration, adhesion and secretion potentials of late endothelial progenitor cells. Cardiovasc Diabetol. 2012, 11 (1): 46-10.1186/1475-2840-11-46.PubMedCentralCrossRefPubMed Li H, Zhang X, Guan X, Cui X, Wang Y, Chu H, Cheng M: Advanced glycation end products impair the migration, adhesion and secretion potentials of late endothelial progenitor cells. Cardiovasc Diabetol. 2012, 11 (1): 46-10.1186/1475-2840-11-46.PubMedCentralCrossRefPubMed
28.
go back to reference Yang K, Wang XQ, He YS, Lu L, Chen QJ, Liu J, Shen WF: Advanced glycation end products induce chemokine/cytokine production via activation of p38 pathway and inhibit proliferation and migration of bone marrow mesenchymal stem cells. Cardiovasc Diabetol. 2010, 9: 66-10.1186/1475-2840-9-66.PubMedCentralCrossRefPubMed Yang K, Wang XQ, He YS, Lu L, Chen QJ, Liu J, Shen WF: Advanced glycation end products induce chemokine/cytokine production via activation of p38 pathway and inhibit proliferation and migration of bone marrow mesenchymal stem cells. Cardiovasc Diabetol. 2010, 9: 66-10.1186/1475-2840-9-66.PubMedCentralCrossRefPubMed
29.
go back to reference Sun L, Ishida T, Yasuda T, Kojima Y, Honjo T, Yamamoto Y, Yamamoto H, Ishibashi S, Hirata K, Hayashi Y: RAGE mediates oxidized LDL-induced pro-inflammatory effects and atherosclerosis in non-diabetic LDL receptor-deficient mice. Cardiovasc Res. 2009, 82 (2): 371-381.CrossRefPubMed Sun L, Ishida T, Yasuda T, Kojima Y, Honjo T, Yamamoto Y, Yamamoto H, Ishibashi S, Hirata K, Hayashi Y: RAGE mediates oxidized LDL-induced pro-inflammatory effects and atherosclerosis in non-diabetic LDL receptor-deficient mice. Cardiovasc Res. 2009, 82 (2): 371-381.CrossRefPubMed
30.
go back to reference Kamioka M, Ishibashi T, Sugimoto K, Uekita H, Nagai R, Sakamoto N, Ando K, Ohkawara H, Teramoto T, Maruyama Y, et al: Blockade of renin-angiotensin system attenuates advanced glycation end products-mediated signaling pathways. J Atheroscler Thromb. 2010, 17 (6): 590-600. 10.5551/jat.3624.CrossRefPubMed Kamioka M, Ishibashi T, Sugimoto K, Uekita H, Nagai R, Sakamoto N, Ando K, Ohkawara H, Teramoto T, Maruyama Y, et al: Blockade of renin-angiotensin system attenuates advanced glycation end products-mediated signaling pathways. J Atheroscler Thromb. 2010, 17 (6): 590-600. 10.5551/jat.3624.CrossRefPubMed
31.
go back to reference Yamagishi S, Matsui T, Nakamura K, Inoue H, Takeuchi M, Ueda S, Fukami K, Okuda S, Imaizumi T: Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression. Microvasc Res. 2008, 75 (1): 130-134. 10.1016/j.mvr.2007.05.001.CrossRefPubMed Yamagishi S, Matsui T, Nakamura K, Inoue H, Takeuchi M, Ueda S, Fukami K, Okuda S, Imaizumi T: Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression. Microvasc Res. 2008, 75 (1): 130-134. 10.1016/j.mvr.2007.05.001.CrossRefPubMed
32.
go back to reference Koka V, Wang W, Huang XR, Kim-Mitsuyama S, Truong LD, Lan HY: Advanced glycation end products activate a chymase-dependent angiotensin II-generating pathway in diabetic complications. Circulation. 2006, 113 (10): 1353-1360. 10.1161/CIRCULATIONAHA.105.575589.PubMedCentralCrossRefPubMed Koka V, Wang W, Huang XR, Kim-Mitsuyama S, Truong LD, Lan HY: Advanced glycation end products activate a chymase-dependent angiotensin II-generating pathway in diabetic complications. Circulation. 2006, 113 (10): 1353-1360. 10.1161/CIRCULATIONAHA.105.575589.PubMedCentralCrossRefPubMed
33.
go back to reference Kotani K, Caccavello R, Sakane N, Yamada T, Taniguchi N, Gugliucci A: Influence of Physical Activity Intervention on Circulating Soluble Receptor for Advanced Glycation end Products in Elderly Subjects. J Clin Med Res. 2011, 3 (5): 252-257.PubMedCentralPubMed Kotani K, Caccavello R, Sakane N, Yamada T, Taniguchi N, Gugliucci A: Influence of Physical Activity Intervention on Circulating Soluble Receptor for Advanced Glycation end Products in Elderly Subjects. J Clin Med Res. 2011, 3 (5): 252-257.PubMedCentralPubMed
34.
go back to reference Hartog JW, Willemsen S, van Veldhuisen DJ, Posma JL, van Wijk LM, Hummel YM, Hillege HL, Voors AA: Effects of alagebrium, an advanced glycation endproduct breaker, on exercise tolerance and cardiac function in patients with chronic heart failure. Eur J Heart Fail. 2011, 13 (8): 899-908. 10.1093/eurjhf/hfr067.CrossRefPubMed Hartog JW, Willemsen S, van Veldhuisen DJ, Posma JL, van Wijk LM, Hummel YM, Hillege HL, Voors AA: Effects of alagebrium, an advanced glycation endproduct breaker, on exercise tolerance and cardiac function in patients with chronic heart failure. Eur J Heart Fail. 2011, 13 (8): 899-908. 10.1093/eurjhf/hfr067.CrossRefPubMed
35.
go back to reference Norton GR, Candy G, Woodiwiss AJ: Aminoguanidine prevents the decreased myocardial compliance produced by streptozotocin-induced diabetes mellitus in rats. Circulation. 1996, 93 (10): 1905-1912. 10.1161/01.CIR.93.10.1905.CrossRefPubMed Norton GR, Candy G, Woodiwiss AJ: Aminoguanidine prevents the decreased myocardial compliance produced by streptozotocin-induced diabetes mellitus in rats. Circulation. 1996, 93 (10): 1905-1912. 10.1161/01.CIR.93.10.1905.CrossRefPubMed
36.
go back to reference Liu J, Masurekar MR, Vatner DE, Jyothirmayi GN, Regan TJ, Vatner SF, Meggs LG, Malhotra A: Glycation end-product cross-link breaker reduces collagen and improves cardiac function in aging diabetic heart. Am J Physiol Heart Circ Physiol. 2003, 285 (6): H2587-2591.CrossRefPubMed Liu J, Masurekar MR, Vatner DE, Jyothirmayi GN, Regan TJ, Vatner SF, Meggs LG, Malhotra A: Glycation end-product cross-link breaker reduces collagen and improves cardiac function in aging diabetic heart. Am J Physiol Heart Circ Physiol. 2003, 285 (6): H2587-2591.CrossRefPubMed
37.
go back to reference Little WC, Zile MR, Kitzman DW, Hundley WG, O'Brien TX, Degroof RC: The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail. 2005, 11 (3): 191-195. 10.1016/j.cardfail.2004.09.010.CrossRefPubMed Little WC, Zile MR, Kitzman DW, Hundley WG, O'Brien TX, Degroof RC: The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail. 2005, 11 (3): 191-195. 10.1016/j.cardfail.2004.09.010.CrossRefPubMed
38.
go back to reference Thohan V, Koemer MM, Pratt CM, Torre GA: Improvements in diastolic function amond patients with advenced systolic heart failure utilizing alagebrium (an oral advanced glycation end-product cross-link breaker). Circulation. 2005, 112 (Suppl 2): U620-2647 Thohan V, Koemer MM, Pratt CM, Torre GA: Improvements in diastolic function amond patients with advenced systolic heart failure utilizing alagebrium (an oral advanced glycation end-product cross-link breaker). Circulation. 2005, 112 (Suppl 2): U620-2647
Metadata
Title
Predictive value of advanced glycation end products for the development of post-infarction heart failure: a preliminary report
Authors
Sergio Raposeiras-Roubín
Bruno K Rodiño-Janeiro
Beatriz Paradela-Dobarro
Lilian Grigorian-Shamagian
José M García-Acuña
Pablo Aguiar-Souto
Michel Jacquet-Hervet
María V Reino-Maceiras
Ezequiel Álvarez
José R González-Juanatey
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2012
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/1475-2840-11-102

Other articles of this Issue 1/2012

Cardiovascular Diabetology 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.